The US Food and Drug Administration has given its approval for Takeda Pharmaceutical to market its hypertension drug in the country.
To be sold under the name of Edarbi, the pill is a derivative of azilsartan medoxomil which is an angiotensin II receptor blocker (ARB).
It helps in blocking out the angiotensin II which is responsible for the constricting of the blood vessels and thereby reduces the blood pressure.
Expressing his delight at receiving the approval, the CEO of Takeda Pharmaceuticals North America, Shinji Honda said, "Through the discovery, development and commercialization of new medicines, Takeda is committed to bringing therapies like EDARBI to market. EDARBI is an important new treatment option for patients with hypertension and the health care professionals who treat them".